



28th April 2026

To

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Scrip Code: 500674

The Secretary
The National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra-Kurla Complex, Bandra (E)
Mumbai 400 051
Symbol: SANOFI

Sub: Outcome of the Board Meeting of the Company

Dear Sirs/Madam,

We refer to our intimation dated 20th April 2026, we hereby inform you that the Board of Directors at its meeting held today i.e., Tuesday, 28th April 2026, *inter-alia*:

1. Considered and approved the Unaudited Financial Results for the quarter ended 31st March 2026.

Accordingly, we enclose a copy of the Limited Review Report, and the Unaudited Financial Results for the quarter ended 31st March 2026, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). A press release in this regard has also been enclosed.

Extract of the aforesaid Results will be published in the newspapers in the format prescribed under Regulation 47 of the Listing Regulations. The aforesaid Financial Results will also be available on the Company's website on [Financial results - Sanofi India](#).

2. Pursuant to Regulation 30 of the Listing Regulations, the Board of Directors have noted/approved the following:
 - a. The tenure of Mr. Aditya Narayan (DIN: 00012084) and Mrs. Usha Thorat (DIN: 00542778) as Independent Directors of the Company will be completed from the close of business hours on Wednesday, 29th April 2026.

The Board of Directors of the Company placed on record its deep appreciation for the invaluable contributions, guidance and services rendered by them during their association as Independent Directors of the Company.

- b. Mr. Rahul Bhatnagar (DIN: 07268064), Independent Director has been appointed as the Chairman of the Board of the Company with effect from Thursday, 30th April 2026.

- c. Re-constitution of the following Committees with effect from Thursday, 30th April, 2026:

Audit Committee:

Sr No	Name of the Member	Category	Position in the Committee
1	Mrs. Rajani Kesari	Independent Director	Chairperson
2	Mr. Siraj Chaudhry	Independent Director	Member
3	Mr. Vaibhav Karandikar	Non-Executive Director	Member

Nomination and Remuneration Committee:

Sr No	Name of the Member	Category	Position in the Committee
1	Mr. Siraj Chaudhry	Independent Director	Chairman
2	Mrs. Rajani Kesari	Independent Director	Member
3	Mr. Eric Mansion	Non-Executive Director	Member

Stakeholders Relationship Committee:

Sr No	Name of the Member	Category	Position in the Committee
1	Mr. Siraj Chaudhry	Independent Director	Chairman
2	Mr. Deepak Arora	Managing Director	Member
3	Mr. Rachid Ayari	Whole-Time Director and Chief Financial Officer	Member

Risk Management Committee:

Sr No	Name of the Member	Category	Position in the Committee
1	Mrs. Rajani Kesari	Independent Director	Chairperson
2	Mr. Siraj Chaudhry	Independent Director	Member
3	Mr. Rachid Ayari	Whole-Time Director and Chief Financial Officer	Member
4	Mr. Mahadev Gawade	Executive Director	Member
5	Mr. Deepak Arora	Managing Director	Member

Corporate Social Responsibility Committee:

Sr No	Name of the Member	Category	Position in the Committee
1	Mr. Siraj Chaudhry	Independent Director	Chairman
2	Mrs. Rajani Kesari	Independent Director	Member
3	Mr. Deepak Arora	Managing Director	Member



The information required in terms of Regulation 30 read with Schedule III of the Listing Regulations and Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 is enclosed as **Annexure I** to this letter.

The meeting of Board of Directors commenced at 2:00 p.m. and concluded at 5:03 p.m.

Please take the above information on record.

Thanking you,
Yours faithfully

For **Sanofi India Limited**

Haresh Vala
Company Secretary and Compliance Officer
Membership No.: A18246

Encl: a/a

Information as required under Regulation 30 read with Schedule III of the Listing Regulations

Completion of tenure of Mr. Aditya Narayan (DIN: 00012084) and Mrs. Usha Thorat (DIN: 00542778) as Independent Directors of the Company:

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Completion of tenure of Mr. Aditya Narayan and Mrs. Usha Thorat as Independent Directors of the Company.
2.	Date of appointment / re-appointment / cessation (as applicable) & term of appointment;	From close of business hours on Wednesday, 29 th April 2026.
3.	Brief profile (in case of appointment)	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Press Release

India



Sanofi India Limited continues to deliver strong performance in insulin portfolio

Mumbai, April 28th, 2026. Sanofi India Limited (SIL) announced its financial results for the quarter ended on March 31, 2026.

In the **Domestic market**, the Insulin portfolio delivered exceptional performance for the second consecutive quarter, achieving **double-digit growth** versus last year and versus previous quarter, demonstrating **Sanofi's established equity in the Diabetes Injectable segment**.

Our strategic partnerships in Cardiovascular (CV), Oral anti Diabetes (OAD) and Central Nervous System (CNS) segments have established a robust foundation.

However, the overall results for this quarter have been impacted by transactions relating to partnership transitions.

Export sales are stabilizing, despite geopolitical situation.

The Company continues to drive significant efficiency improvements through targeted market initiatives, refined go-to-market strategies, and operational excellence programs.

Deepak Arora

Managing director

*"Despite current focus on newer diabetes therapies, our **14% registered growth** (vs previous quarter) and **19% registered growth** (vs last year) validates what clinical guidelines consistently affirm: **insulin remains essential for comprehensive diabetes care**. Our success across both public and private sectors reflects the medical community's continued trust in insulin as the **gold standard for reliable, predictable diabetes management** — a position that remains unshakeable regardless of market trends.*

Our strategic partnerships will catalyse growth, strengthen our commercial footprint, enhance market penetration, and create meaningful connections with healthcare professionals across therapeutic areas.

We remain committed to driving operational excellence while broadening access to both established and innovative therapies, throughout India."

Sanofi in India

Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people's lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.

Sanofi's India Charitable Access Program (InCAP) is the country's longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from the company's global pipeline. Sanofi India's world-class manufacturing site in Goa produces for people in India and 24+ other countries. Sanofi has located one of its four global talent hubs

in Hyderabad, India, from where wide range of services are provided globally.

Recognized by the 'Top® Employers Institute' – a global authority that honours excellence in people practices since 2019, Sanofi's local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL).

For more information, visit: www.sanofi.com/en/in, [LinkedIn](#) and [Twitter](#).

Media Relations

Vinifer Gandhi | vinifer.gandhi@sanofi.com

Price Waterhouse & Co Chartered Accountants LLP

Review Report

To
The Board of Directors
Sanofi India Limited
CTS No. 117-B, L&T Business Park,
Saki Vihar Road, Powai,
Mumbai 400 072

1. We have reviewed the unaudited financial results of Sanofi India Limited (the “Company”) for the quarter ended March 31, 2026, which are included in the accompanying ‘Statement of Unaudited Financial Results for the quarter ended March 31, 2026’ (the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations, 2015”), which has been digitally signed by us for identification purposes. The Statement is the responsibility of the Company’s management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/E-300009

Arunkumar Ramdas
Partner
Membership Number: 112433
UDIN: 26112433XBGUTB3474

Place: Mumbai
Date: April 28, 2026

Price Waterhouse & Co Chartered Accountants LLP, Nesco IT Building III, 8th Floor, Nesco IT Park, Nesco Complex Gate No. 3 Western Express Highway, Goregaon East, Mumbai 400 063
T: +91 (22) 61197808

Registered office and Head office: Plot No. 56 & 57, Block ON, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)

SANOFI INDIA LIMITED

Registered Office : Sanofi House,C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.
Corporate Identity Number: L24239MH1956PLC009794
Tel no: (91-22) 28032000 Fax No: (91-22) 28032846
Website: www.sanofiindia.com Email: igrc.sil@sanofi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026

Particulars	₹ in Million			
	Quarter ended 31.03.2026 (Unaudited)	Quarter ended 31.12.2025 (Unaudited) (Refer Note 4)	Quarter ended 31.03.2025 (Unaudited)	Year ended 31.12.2025 (Audited)
1. Revenue from Operations	4,723	4,198	5,359	18,374
2. Other Income	44	28	33	197
3. Total Income (1+2)	4,767	4,226	5,392	18,571
4. Expenses				
(a) Cost of Materials Consumed	503	553	757	2,464
(b) Purchases of stock-in-trade	1,482	1,245	841	5,140
(c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods	358	283	807	1,368
(d) Employee benefits expense	428	447	538	1,853
(e) Finance costs	3	6	3	17
(f) Depreciation and amortisation expense	90	95	96	373
(g) Other expenses	524	767	697	2,636
Total Expenses	3,388	3,396	3,739	13,851
5. Profit before exceptional items and tax (3-4)	1,379	830	1,653	4,720
6. Exceptional items (Refer note 3)	-	-	-	(273)
7. Profit before tax (5+6)	1,379	830	1,653	4,447
8. Income tax expense				
Current Tax	343	210	457	1,229
Deferred Tax	10	3	1	(49)
9. Profit for the period /year (7-8)	1,026	617	1,195	3,267
10. Other comprehensive income (OCI) (Net of Tax)	-	17	-	17
11. Total comprehensive income for the period/year (9+10)	1,026	634	1,195	3,284
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230
13. Other equity	-	-	-	7,262
14. Basic and diluted earnings per share (not annualised) (in ₹)	44.55	26.79	51.89	141.85

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated April 28, 2026

Notes:

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on April 28, 2026. The statutory auditors have carried out a limited review of the above results for the quarter ended March 31, 2026.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
3. Exceptional items relate to personnel separation costs of ₹273 million for the year ended December 31, 2025.
4. The figures for the quarter ended December 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and published year to date figures upto third quarter of the financial year.
5. The Company has a single business segment namely 'Pharmaceutical Business'.

SANOFI INDIA LIMITED

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated April 28, 2026

DEEPAK ARORA
MANAGING DIRECTOR
DIN: 07495638

April 28, 2026